• Platform & Pipeline
    • Opportunity
    • CAR T-Cell Therapy
    • Pipeline
    • Clinical Trials and Expanded Access
  • Patients
    • Experience
    • Stiff Person Syndrome
    • Myasthenia Gravis
    • Multiple Sclerosis
  • Inside Kyverna
    • Leadership
    • Mission & Values
  • Knowledge Center
    • Publications
    • Videos
  • Investors
  • News
  • Careers
  • Contact
← Back

Browse Jobs

Clinical

Senior Director, Clinical Science

Remote
View

Commercial

Cell Therapy Account Management Specialist - Central/Mountain

Remote
View

Cell Therapy Account Management Specialist - Great Lakes/Southeast

Remote
View

Cell Therapy Account Management Specialist - Mid-Atlantic/Northeast

Remote
View

Cell Therapy Account Management Specialist - Pacific

Remote
View

Sr. Director, Marketing Promotions

Emeryville, CA
View

Vice President, Sales

Remote
View

Drug Safety/Pharmacovigilance

Safety Writer/Scientist – Contract

Remote
View

Medical Affairs

Director of Training, Global Medical Affairs

Remote
View

Medical Science Liaison/Senior Medical Science Liaison – (Great Lakes)

Remote
View

Medical Science Liaison/Senior Medical Science Liaison – (Ohio Valley)

Remote
View

Medical Science Liaison/Senior Medical Science Liaison – (Southcentral)

Remote
View

Medical Science Liaison/Senior Medical Science Liaison – (Southwest)

Remote
View

Project Management

Executive Director, Lifecycle Lead

Remote
View

Regulatory Affairs

Executive Director, Medical Writing

Remote
View

Executive Director, Regulatory Affairs

Remote
View

Sr Manager, Medical Writing

Remote
View

Links

  • Home
  • Platform & Pipeline
  • Patients
  • Inside Kyverna
  • Knowledge Center
  • Investors
  • Careers
  • Contact

About

Kyverna is a late-stage clinical immunology company pioneering differentiated therapies with curative potential for neurologic autoimmune diseases.

Our lead autologous CD19-targeting CAR T-cell therapy candidate, miv-cel (mivocabtagene autoleucel, KYV-101), has demonstrated the potential to fundamentally change the treatment paradigm across multiple B-cell-driven autoimmune diseases. Kyverna is advancing its potentially first-in-class neuroimmunology franchise with its recently completed registrational trial in stiff person syndrome and an ongoing registrational trial for generalized myasthenia gravis.

Kyverna is also harnessing other KYSA trials and investigator-initiated trials, as well as next generation innovations to expand patient access and evaluate future indications.

FOLLOW US ON SOCIAL

  • Privacy Policy (US)
  • Privacy Policy (EU/UK)

Designed by Elegant Themes | Powered by WordPress